Overview
Francesca Paino practices practicing medicine in Milan, Italy.
Her clinical expertise encompasses Mesothelioma, Osteosarcoma, Triple-Negative Breast Cancer, and Bone Graft.
She is actively involved in clinical research, co-authoring 40 peer reviewed articles.
Gender
Locations
Clinical Research
Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.
Frequently Asked Questions about Francesca Paino
Is Francesca Paino a top-rated expert for Mesothelioma?
MediFind is an objective health platform that identifies experts based on real-world data. Francesca Paino is classified as an Experienced expert for Mesothelioma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.
Does Francesca Paino participate in research or clinical trials?
Yes. Francesca Paino has published 40 articles and abstracts on conditions like Mesothelioma. You can view a list of Francesca Paino's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.
Areas of Expertise
MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.
Learn more about MediFind’s expert tiers
- Experienced
- Bone GraftMs. Paino isExperienced. Learn about Bone Graft.
- MesotheliomaMs. Paino isExperienced. Learn about Mesothelioma.
- OsteosarcomaMs. Paino isExperienced. Learn about Osteosarcoma.
- Triple-Negative Breast CancerMs. Paino isExperienced. Learn about Triple-Negative Breast Cancer.